Emcure doubling down on biosimilars pipeline: MD Satish Mehta
Subscribe to enjoy similar stories.Mumbai: Emcure Pharmaceuticals plans to expand its biosimilars pipeline to ride a slew of patent expiries as well as favourable tailwinds on global demand, the company’s top executive told Mint in an interview.“We have identified biosimilars as a growth driver. In the next three to five years, a lot of our R&D spend as well as portfolio contribution would be skewed towards biosimilars as well as some of the larger peptides and the ADC (antibody drug conjugates) program,” managing director and chief executive Satish Mehta said.Pune-headquartered Emcure is largely a generics drug manufacturer, but is ramping up focus on specialty products like complex injectables, biologics and antibody drug conjugates.
The company does not give a product-wise revenue split.The company currently has six biosimilars in the market, launched through its subsidiary Gennova Biopharmaceuticals. So far, Emcure has developed these in-house.
Read on livemint.com